This Experimental Pill Could Become the First-Ever Drug for Cocaine Addiction

An experimental drug called mavoglurant can reduce the consumption of alcohol and cocaine in people with drug use disorder, according to the results of a new phase 2 clinical trial with 68 participants.

This Experimental Pill Could Become the First-Ever Drug for Cocaine Addiction

In a small Phase II trial, people with cocaine use disorder who took mavoglurant used the drug less often over a three month period than those on a placebo.

For the first time, there may be an effective drug treatment for drug abuse. According to the latest studies, an experimental drug called mavoglurant is effective.

A failed fragile X syndrome drug can reduce cocaine use, clinical trial finds

A team of pharmaceutical researchers at Novartis Biomedical Research, working with an international team of associates, has found that the drug mavoglurant can reduce use in people with cocaine use disorder. In their study, published in the journal Science Translational Medicine, the group conducted a Phase II clinical trial with 68 people with a diagnosed cocaine use disorder.

New clinical trial tests Mavoglurant, a medication that can reduce the consumption of alcohol and cocaine in people with a disorder due to the use of this drug. Results are positive, but researchers admit that it is necessary to enlarge the sample and prolong the analysis over time

Overall, the group that received mavoglurant consumed cocaine in fewer days and showed evidence of lower alcohol intake.